BioNTech (NASDAQ:BNTX) Sees Strong Trading Volume

Shares of BioNTech SE (NASDAQ:BNTX - Get Free Report) saw strong trading volume on Tuesday . 308,533 shares traded hands during trading, a decline of 53% from the previous session's volume of 653,009 shares.The stock last traded at $86.80 and had previously closed at $87.89.

Analyst Ratings Changes

Several research analysts have weighed in on the company. UBS Group lowered their price objective on BioNTech from $110.00 to $101.00 and set a "neutral" rating on the stock in a research report on Wednesday, March 27th. The Goldman Sachs Group lowered their price objective on BioNTech from $113.00 to $100.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 28th. BMO Capital Markets lowered their price objective on BioNTech from $127.00 to $123.00 and set an "outperform" rating on the stock in a research report on Thursday, March 21st. JPMorgan Chase & Co. lowered their price objective on BioNTech from $99.00 to $90.00 and set an "underweight" rating on the stock in a research report on Friday, March 22nd. Finally, Oppenheimer assumed coverage on BioNTech in a research report on Friday, January 5th. They set a "market perform" rating on the stock. One research analyst has rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $120.40.

BioNTech Stock Down 1.8 %

The company has a debt-to-equity ratio of 0.01, a current ratio of 9.43 and a quick ratio of 9.26. The company has a market cap of $20.53 billion, a P/E ratio of 20.96 and a beta of 0.23. The stock has a 50-day moving average of $91.67 and a 200 day moving average of $97.64.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings data on Wednesday, March 20th. The company reported $2.05 earnings per share for the quarter, missing the consensus estimate of $2.64 by ($0.59). The business had revenue of $1.59 billion during the quarter, compared to analyst estimates of $2.04 billion. BioNTech had a net margin of 24.26% and a return on equity of 4.60%. Research analysts anticipate that BioNTech SE will post -1.67 earnings per share for the current year.

Institutional Trading of BioNTech

Several large investors have recently bought and sold shares of BNTX. GAMMA Investing LLC boosted its stake in BioNTech by 121.0% in the first quarter. GAMMA Investing LLC now owns 274 shares of the company's stock valued at $25,000 after buying an additional 150 shares in the last quarter. State of Wyoming acquired a new stake in shares of BioNTech during the second quarter valued at about $26,000. CWM LLC boosted its stake in shares of BioNTech by 657.6% during the fourth quarter. CWM LLC now owns 250 shares of the company's stock valued at $26,000 after purchasing an additional 217 shares in the last quarter. Frazier Financial Advisors LLC acquired a new stake in shares of BioNTech during the fourth quarter valued at about $30,000. Finally, Covestor Ltd acquired a new stake in shares of BioNTech during the third quarter valued at about $32,000. 15.52% of the stock is owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.